⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 25, 2021SHILAP Revista de lepidopterologíaOpen Access

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma

View Full Paper

Ask AI

Bookmark

Share

Abstract

Compared to PL, HPL was associated with a significantly better treatment response and survival benefits for patients with advanced HCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mei et al. (2021) studied this question.

synapsesocial.com/papers/69dad7608988aeabbe687d74 https://doi.org/10.3389/fonc.2021.618206

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2018 · 88,323 citations
2Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular CarcinomaEarly-Phase Clinical Trial · 2020 · 1,191 citations
3Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cellsOriginal Research · 2016 · 29 citations
4Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRCT · 2019 · 1,843 citations
5TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cellsOriginal Research · 2012 · 101 citations